Karine
Breckpot
Technologieën die worden of werden geïmplementeerd zijn: dendritische cel vaccinatie, mRNA vaccinatie, lentivirale technologie, gebruik van antilichaam fragmenten en hieraan gelinkt drug conjugaten.
Contact
Talenkennis
Achtergrond
Opleidingsraad Biomedische Wetenschappen (sinds 2000),
Facultaire Raad (sinds 2011),
Examencommissie Biomedische Wetenschappen (sinds 2013),
Voorzitter van de Ethische Commissie Dierproeven (sinds 2014).
Lid van UMCOR (Universitair Medicsh Center Onderzoeksraad) en UMCOR bureau (sinds 2015 en 2016, resp.).
Lid van expert panels voor peer-reviewed journals (e.g. Science Translational Medicine, Biomaterials, Nanomedicine, Molecular Therapy, Vaccine, etc.).
Lid van expert panels voor (inter)nationale agentschappen die onderzoek ondersteunen, waaronder (voormalig) IWT (België), FWO (België), Leukemia & Lymphoma Research (UK), National Research Foundation (South Africa), Austrian Science Fund (Austria), Agence National de Recherche (France), Research Grant Council Hong Kong (RGC), Cancer Research UK (UK), KWF (the Netherlands), National Science Center (Poland), Agenzia Italiana del Farmaca (Italy), International Myeloma Foundation (USA).
Lid van het VLIR ad hoc committee dat advies geeft ron de wetgeving aangaande dierproeven.
Studie(s) en diploma's
PhD in Medische Wetenschappen (Vrije Universiteit Brussel).
Huidige functieomschrijving
Professor in de immunologie aan de Vrije Universiteit Brussel.
Ervaring
Onderzoek in kanker immunologie en immuuntherapie in samenwerking met academische, medische en industriële partners.
Relevante Publicaties
|
1. |
Challenges in neoantigen-directed therapeutics.
Lybaert L, Lefever S, Fant B, Smits E, De Geest B, Breckpot K, Dirix L, Feldman SA, van Criekinge W, Thielemans K, van der Burg SH, Ott PA, Bogaert C. Cancer Cell. 2022 Nov 7:S1535-6108(22)00504-9. doi: 10.1016/j.ccell.2022.10.013. Online ahead of print. PMID: 36368320 Review. |
|
2. |
The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers.
Fan R, De Beule N, Maes A, De Bruyne E, Menu E, Vanderkerken K, Maes K, Breckpot K, De Veirman K. Front Immunol. 2022 Oct 11;13:1016059. doi: 10.3389/fimmu.2022.1016059. eCollection 2022. PMID: 36304465 Free PMC article. Review. |
|
3. |
A synthetic DNA template for fast manufacturing of versatile single epitope mRNA.
de Mey W, De Schrijver P, Autaers D, Pfitzer L, Fant B, Locy H, Esprit A, Lybaert L, Bogaert C, Verdonck M, Thielemans K, Breckpot K, Franceschini L. Mol Ther Nucleic Acids. 2022 Aug 17;29:943-954. doi: 10.1016/j.omtn.2022.08.021. eCollection 2022 Sep 13. PMID: 36159589 Free PMC article. |
|
4. |
mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells.
Bevers S, Kooijmans SAA, Van de Velde E, Evers MJW, Seghers S, Gitz-Francois JJJM, van Kronenburg NCH, Fens MHAM, Mastrobattista E, Hassler L, Sork H, Lehto T, Ahmed KE, El Andaloussi S, Fiedler K, Breckpot K, Maes M, Van Hoorick D, Bastogne T, Schiffelers RM, De Koker S. Mol Ther. 2022 Sep 7;30(9):3078-3094. doi: 10.1016/j.ymthe.2022.07.007. Epub 2022 Jul 12. PMID: 35821637 Free PMC article. |
|
5. |
Emerging applications of nanobodies in cancer therapy.
Awad RM, Meeus F, Ceuppens H, Ertveldt T, Hanssens H, Lecocq Q, Mateusiak L, Zeven K, Valenta H, De Groof TWM, De Vlaeminck Y, Krasniqi A, De Veirman K, Goyvaerts C, D'Huyvetter M, Hernot S, Devoogdt N, Breckpot K. Int Rev Cell Mol Biol. 2022;369:143-199. doi: 10.1016/bs.ircmb.2022.03.010. Epub 2022 May 18. PMID: 35777863 |
|
6. |
Inhibiting Histone and DNA Methylation Improves Cancer Vaccination in an Experimental Model of Melanoma.
De Beck L, Awad RM, Basso V, Casares N, De Ridder K, De Vlaeminck Y, Gnata A, Goyvaerts C, Lecocq Q, San José-Enériz E, Verhulst S, Maes K, Vanderkerken K, Agirre X, Prosper F, Lasarte JJ, Mondino A, Breckpot K. Front Immunol. 2022 May 12;13:799636. doi: 10.3389/fimmu.2022.799636. eCollection 2022. PMID: 35634329 Free PMC article. |
|
7. |
RNA in Cancer Immunotherapy: Unlocking the Potential of the Immune System.
De Mey W, Esprit A, Thielemans K, Breckpot K, Franceschini L. Clin Cancer Res. 2022 Sep 15;28(18):3929-3939. doi: 10.1158/1078-0432.CCR-21-3304. PMID: 35583609 Review. |
|
8. |
Oncolytic Herpes Simplex Virus Type 1 Induces Immunogenic Cell Death Resulting in Maturation of BDCA-1+Myeloid Dendritic Cells.
Kalus P, De Munck J, Vanbellingen S, Carreer L, Laeremans T, Broos K, Dufait I, Schwarze JK, Van Riet I, Neyns B, Breckpot K, Aerts JL. Int J Mol Sci. 2022 Apr 27;23(9):4865. doi: 10.3390/ijms23094865. PMID: 35563257 Free PMC article. |
|
9. |
Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177-Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model.
Ertveldt T, De Beck L, De Ridder K, Locy H, de Mey W, Goyvaerts C, Lecocq Q, Ceuppens H, De Vlaeminck Y, Awad RM, Keyaerts M, Devoogdt N, D'Huyvetter M, Breckpot K, Krasniqi A. Mol Cancer Ther. 2022 Jul 5;21(7):1136-1148. doi: 10.1158/1535-7163.MCT-21-0791. PMID: 35499391 |
|
10. |
TNF-α-Secreting Lung Tumor-Infiltrated Monocytes Play a Pivotal Role During Anti-PD-L1 Immunotherapy.
De Ridder K, Locy H, Piccioni E, Zuazo MI, Awad RM, Verhulst S, Van Bulck M, De Vlaeminck Y, Lecocq Q, Reijmen E, De Mey W, De Beck L, Ertveldt T, Pintelon I, Timmermans JP, Escors D, Keyaerts M, Breckpot K, Goyvaerts C. Front Immunol. 2022 Apr 14;13:811867. doi: 10.3389/fimmu.2022.811867. eCollection 2022. PMID: 35493461 Free PMC article. |
|
11. |
Assessing Tumor-Infiltrating Lymphocytes in Breast Cancer: A Proposal for Combining Immunohistochemistry and Gene Expression Analysis to Refine Scoring.
Locy H, Verhulst S, Cools W, Waelput W, Brock S, Cras L, Schiettecatte A, Jonckheere J, van Grunsven LA, Vanhoeij M, Thielemans K, Breckpot K. Front Immunol. 2022 Feb 11;13:794175. doi: 10.3389/fimmu.2022.794175. eCollection 2022. PMID: 35222378 Free PMC article. |
|
12. |
CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma.
De Veirman K, Puttemans J, Krasniqi A, Ertveldt T, Hanssens H, Romao E, Hose D, Goyvaert C, Vlummens P, Muyldermans S, Breckpot K, Bruchertseifer F, Morgenstern A, D'Huyvetter M, Devoogdt N. Oncoimmunology. 2021 Nov 9;10(1):2000699. doi: 10.1080/2162402X.2021.2000699. eCollection 2021. PMID: 34777918 Free PMC article. |
|
13. |
Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells.
Tijtgat J, De Munck J, Dufait I, Schwarze JK, Van Riet I, Franceschini L, Breckpot K, Aerts JL, Neyns B, Tuyaerts S. Front Immunol. 2021 Oct 28;12:733506. doi: 10.3389/fimmu.2021.733506. eCollection 2021. PMID: 34777344 Free PMC article. |
|
14. |
Evaluation of single domain antibodies as nuclear tracers for imaging of the immune checkpoint receptor human lymphocyte activation gene-3 in cancer.
Lecocq Q, Debie P, Puttemans J, Awad RM, De Beck L, Ertveldt T, De Vlaeminck Y, Goyvaerts C, Raes G, Keyaerts M, Breckpot K, Devoogdt N. EJNMMI Res. 2021 Nov 2;11(1):115. doi: 10.1186/s13550-021-00857-9. PMID: 34727262 Free PMC article. |
|
15. |
T-cell subsets in the skin and their role in inflammatory skin disorders.
Kortekaas Krohn I, Aerts JL, Breckpot K, Goyvaerts C, Knol E, Van Wijk F, Gutermuth J. Allergy. 2022 Mar;77(3):827-842. doi: 10.1111/all.15104. Epub 2021 Oct 6. PMID: 34559894 Review. |
|
16. |
Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade.
Awad RM, Lecocq Q, Zeven K, Ertveldt T, De Beck L, Ceuppens H, Broos K, De Vlaeminck Y, Goyvaerts C, Verdonck M, Raes G, Van Parys A, Cauwels A, Keyaerts M, Devoogdt N, Breckpot K. Mol Ther Methods Clin Dev. 2021 Jun 4;22:172-182. doi: 10.1016/j.omtm.2021.05.017. eCollection 2021 Sep 10. PMID: 34485603 Free PMC article. |
|
17. |
Site-Specific Radiolabeling of a Human PD-L1 Nanobody via Maleimide-Cysteine Chemistry.
Chigoho DM, Lecocq Q, Awad RM, Breckpot K, Devoogdt N, Keyaerts M, Caveliers V, Xavier C, Bridoux J. Pharmaceuticals (Basel). 2021 Jun 8;14(6):550. doi: 10.3390/ph14060550. PMID: 34201323 Free PMC article. |
|
18. |
The antigen-binding moiety in the driver's seat of CARs.
Hanssens H, Meeus F, De Veirman K, Breckpot K, Devoogdt N. Med Res Rev. 2022 Jan;42(1):306-342. doi: 10.1002/med.21818. Epub 2021 May 24. PMID: 34028069 Free PMC article. Review. |
|
19. |
Overcoming the Challenges of High Quality RNA Extraction from Core Needle Biopsy.
Locy H, Correa RJM, Autaers D, Schiettecatte A, Jonckheere J, Waelput W, Cras L, Brock S, Verhulst S, Kwan K, Vanhoeij M, Thielemans K, Breckpot K. Biomolecules. 2021 Apr 22;11(5):621. doi: 10.3390/biom11050621. PMID: 33922016 Free PMC article. |
|
20. |
Fractionated Radiation Severely Reduces the Number of CD8+ T Cells and Mature Antigen Presenting Cells Within Lung Tumors.
Reijmen E, De Mey S, De Mey W, Gevaert T, De Ridder K, Locy H, Martens S, De Blay E, Bouwens L, Debie P, Breckpot K, De Grève J, De Ridder M, Goyvaerts C. Int J Radiat Oncol Biol Phys. 2021 Sep 1;111(1):272-283. doi: 10.1016/j.ijrobp.2021.04.009. Epub 2021 Apr 15. PMID: 33865948 |
|
21. |
Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential.
Maes K, Mondino A, Lasarte JJ, Agirre X, Vanderkerken K, Prosper F, Breckpot K. Front Immunol. 2021 Mar 30;12:652160. doi: 10.3389/fimmu.2021.652160. eCollection 2021. PMID: 33859645 Free PMC article. Review. |
|
22. |
Immunogenicity Risk Profile of Nanobodies.
Ackaert C, Smiejkowska N, Xavier C, Sterckx YGJ, Denies S, Stijlemans B, Elkrim Y, Devoogdt N, Caveliers V, Lahoutte T, Muyldermans S, Breckpot K, Keyaerts M. Front Immunol. 2021 Mar 9;12:632687. doi: 10.3389/fimmu.2021.632687. eCollection 2021. PMID: 33767701 Free PMC article. |
|
23. |
Single-Domain Antibody Nuclear Imaging Allows Noninvasive Quantification of LAG-3 Expression by Tumor-Infiltrating Leukocytes and Predicts Response of Immune Checkpoint Blockade.
Lecocq Q, Awad RM, De Vlaeminck Y, de Mey W, Ertveldt T, Goyvaerts C, Raes G, Thielemans K, Keyaerts M, Devoogdt N, Breckpot K. J Nucl Med. 2021 Nov;62(11):1638-1644. doi: 10.2967/jnumed.120.258871. Epub 2021 Mar 12. PMID: 33712537 Free PMC article. |
|
24. |
mRNA in cancer immunotherapy: beyond a source of antigen.
Van Hoecke L, Verbeke R, Dewitte H, Lentacker I, Vermaelen K, Breckpot K, Van Lint S. Mol Cancer. 2021 Mar 3;20(1):48. doi: 10.1186/s12943-021-01329-3. PMID: 33658037 Free PMC article. Review. |
|
25. |
The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time's a Charm.
Lecocq Q, Keyaerts M, Devoogdt N, Breckpot K. Int J Mol Sci. 2020 Dec 23;22(1):75. doi: 10.3390/ijms22010075. PMID: 33374804 Free PMC article. Review. |
|
26. |
Neo-Antigen mRNA Vaccines.
Esprit A, de Mey W, Bahadur Shahi R, Thielemans K, Franceschini L, Breckpot K. Vaccines (Basel). 2020 Dec 18;8(4):776. doi: 10.3390/vaccines8040776. PMID: 33353155 Free PMC article. Review. |
|
27. |
Targeting Neuropilin-1 with Nanobodies Reduces Colorectal Carcinoma Development.
De Vlaeminck Y, Bonelli S, Awad RM, Dewilde M, Rizzolio S, Lecocq Q, Bolli E, Santos AR, Laoui D, Schoonooghe S, Tamagnone L, Goyvaerts C, Mazzone M, Breckpot K, Van Ginderachter JA. Cancers (Basel). 2020 Nov 30;12(12):3582. doi: 10.3390/cancers12123582. PMID: 33266104 Free PMC article. |
|
28. |
Hepatocarcinoma Induces a Tumor Necrosis Factor-Dependent Kupffer Cell Death Pathway That Favors Its Proliferation Upon Partial Hepatectomy.
Hastir JF, Delbauve S, Larbanoix L, Germanova D, Goyvaerts C, Allard J, Laurent S, Breckpot K, Beschin A, Guilliams M, Flamand V. Front Oncol. 2020 Oct 16;10:547013. doi: 10.3389/fonc.2020.547013. eCollection 2020. PMID: 33178579 Free PMC article. |
|
29. |
Anti-human PD-L1 Nanobody for Immuno-PET Imaging: Validation of a Conjugation Strategy for Clinical Translation.
Bridoux J, Broos K, Lecocq Q, Debie P, Martin C, Ballet S, Raes G, Neyt S, Vanhove C, Breckpot K, Devoogdt N, Caveliers V, Keyaerts M, Xavier C. Biomolecules. 2020 Sep 29;10(10):1388. doi: 10.3390/biom10101388. PMID: 33003481 Free PMC article. |
|
30. |
Preclinical Targeted α- and β--Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies.
Puttemans J, Dekempeneer Y, Eersels JL, Hanssens H, Debie P, Keyaerts M, Windhorst AD, van der Aa F, Lecocq Q, Breckpot K, Morgenstern A, Bruchertseifer F, Lahoutte T, Devoogdt N, D'Huyvetter M. Cancers (Basel). 2020 Apr 21;12(4):1017. doi: 10.3390/cancers12041017. PMID: 32326199 Free PMC article. |
|
31. |
Theranostics in immuno-oncology using nanobody derivatives.
Lecocq Q, De Vlaeminck Y, Hanssens H, D'Huyvetter M, Raes G, Goyvaerts C, Keyaerts M, Devoogdt N, Breckpot K. Theranostics. 2019 Oct 15;9(25):7772-7791. doi: 10.7150/thno.34941. eCollection 2019. PMID: 31695800 Free PMC article. Review. |
|
32. |
Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use.
Lecocq Q, Zeven K, De Vlaeminck Y, Martens S, Massa S, Goyvaerts C, Raes G, Keyaerts M, Breckpot K, Devoogdt N. Biomolecules. 2019 Sep 29;9(10):548. doi: 10.3390/biom9100548. PMID: 31569553 Free PMC article. |
|
33. |
Commentary: Immunogenic Cell Death and Immunotherapy of Multiple Myeloma.
Maes K, Breckpot K. Front Cell Dev Biol. 2019 Jul 31;7:149. doi: 10.3389/fcell.2019.00149. eCollection 2019. PMID: 31417904 Free PMC article. No abstract available. |
|
34. |
Single Domain Antibody-Mediated Blockade of Programmed Death-Ligand 1 on Dendritic Cells Enhances CD8 T-cell Activation and Cytokine Production.
Broos K, Lecocq Q, Keersmaecker B, Raes G, Corthals J, Lion E, Thielemans K, Devoogdt N, Keyaerts M, Breckpot K. Vaccines (Basel). 2019 Aug 7;7(3):85. doi: 10.3390/vaccines7030085. PMID: 31394834 Free PMC article. |
|
35. |
Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent.
Broos K, Lecocq Q, Xavier C, Bridoux J, Nguyen TT, Corthals J, Schoonooghe S, Lion E, Raes G, Keyaerts M, Devoogdt N, Breckpot K. Cancers (Basel). 2019 Jun 21;11(6):872. doi: 10.3390/cancers11060872. PMID: 31234464 Free PMC article. |
|
36. |
Perforin and Granzyme B Expressed by Murine Myeloid-Derived Suppressor Cells: A Study on Their Role in Outgrowth of Cancer Cells.
Dufait I, Pardo J, Escors D, De Vlaeminck Y, Jiang H, Keyaerts M, De Ridder M, Breckpot K. Cancers (Basel). 2019 Jun 11;11(6):808. doi: 10.3390/cancers11060808. PMID: 31212684 Free PMC article. |
|
37. |
Towards a personalized iPSC-based vaccine.
Goyvaerts C, Breckpot K. Nat Biomed Eng. 2018 May;2(5):277-278. doi: 10.1038/s41551-018-0237-7. PMID: 30936451 No abstract available. |
|
38. |
Single-domain antibody fusion proteins can target and shuttle functional proteins into macrophage mannose receptor expressing macrophages.
De Vlaeminck Y, Lecocq Q, Giron P, Heirman C, Geeraerts X, Bolli E, Movahedi K, Massa S, Schoonooghe S, Thielemans K, Goyvaerts C, Van Ginderachter JA, Breckpot K. J Control Release. 2019 Apr 10;299:107-120. doi: 10.1016/j.jconrel.2019.02.023. Epub 2019 Feb 21. PMID: 30797866 |
|
39. |
Broadening the Message: A Nanovaccine Co-loaded with Messenger RNA and α-GalCer Induces Antitumor Immunity through Conventional and Natural Killer T Cells.
Verbeke R, Lentacker I, Breckpot K, Janssens J, Van Calenbergh S, De Smedt SC, Dewitte H. ACS Nano. 2019 Feb 26;13(2):1655-1669. doi: 10.1021/acsnano.8b07660. Epub 2019 Feb 15. PMID: 30742405 |
|
40. |
Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects.
De Beck L, Melhaoui S, De Veirman K, Menu E, De Bruyne E, Vanderkerken K, Breckpot K, Maes K. Oncoimmunology. 2018 Jul 23;7(10):e1484981. doi: 10.1080/2162402X.2018.1484981. eCollection 2018. PMID: 30288346 Free PMC article. |
|
41. |
Dendritic Cell Targeting mRNA Lipopolyplexes Combine Strong Antitumor T-Cell Immunity with Improved Inflammatory Safety.
Van der Jeught K, De Koker S, Bialkowski L, Heirman C, Tjok Joe P, Perche F, Maenhout S, Bevers S, Broos K, Deswarte K, Malard V, Hammad H, Baril P, Benvegnu T, Jaffrès PA, Kooijmans SAA, Schiffelers R, Lienenklaus S, Midoux P, Pichon C, Breckpot K, Thielemans K. ACS Nano. 2018 Oct 23;12(10):9815-9829. doi: 10.1021/acsnano.8b00966. Epub 2018 Oct 1. PMID: 30256609 |
|
42. |
The Journey of in vivo Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road.
Goyvaerts C, Breckpot K. Front Immunol. 2018 Sep 11;9:2052. doi: 10.3389/fimmu.2018.02052. eCollection 2018. PMID: 30254636 Free PMC article. Review. |
|
43. |
Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression.
Awad RM, De Vlaeminck Y, Maebe J, Goyvaerts C, Breckpot K. Front Immunol. 2018 Aug 31;9:1977. doi: 10.3389/fimmu.2018.01977. eCollection 2018. PMID: 30233579 Free PMC article. Review. |
|
44. |
Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy.
Broos K, Lecocq Q, Raes G, Devoogdt N, Keyaerts M, Breckpot K. Theranostics. 2018 Jun 7;8(13):3559-3570. doi: 10.7150/thno.24762. eCollection 2018. PMID: 30026866 Free PMC article. Review. |
|
45. |
A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches.
Versteven M, Van den Bergh JMJ, Broos K, Fujiki F, Campillo-Davo D, De Reu H, Morimoto S, Lecocq Q, Keyaerts M, Berneman Z, Sugiyama H, Van Tendeloo VFI, Breckpot K, Lion E. Oncotarget. 2018 Jun 12;9(45):27797-27808. doi: 10.18632/oncotarget.25591. eCollection 2018 Jun 12. PMID: 29963238 Free PMC article. |
|
46. |
Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.
De Smedt E, Maes K, Verhulst S, Lui H, Kassambara A, Maes A, Robert N, Heirman C, Cakana A, Hose D, Breckpot K, van Grunsven LA, De Veirman K, Menu E, Vanderkerken K, Moreaux J, De Bruyne E. Cancer Res. 2018 Mar 1;78(5):1155-1168. doi: 10.1158/0008-5472.CAN-17-1544. Epub 2017 Dec 19. PMID: 29259009 |
|
47. |
Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: Restoring the immunogenicity of immunosilent mRNA.
Verbeke R, Lentacker I, Wayteck L, Breckpot K, Van Bockstal M, Descamps B, Vanhove C, De Smedt SC, Dewitte H. J Control Release. 2017 Nov 28;266:287-300. doi: 10.1016/j.jconrel.2017.09.041. Epub 2017 Oct 5. PMID: 28987878 |
|
48. |
PD1 signal transduction pathways in T cells.
Arasanz H, Gato-Cañas M, Zuazo M, Ibañez-Vea M, Breckpot K, Kochan G, Escors D. Oncotarget. 2017 Apr 19;8(31):51936-51945. doi: 10.18632/oncotarget.17232. eCollection 2017 Aug 1. PMID: 28881701 Free PMC article. Review. |
|
49. |
PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity.
Gato-Cañas M, Zuazo M, Arasanz H, Ibañez-Vea M, Lorenzo L, Fernandez-Hinojal G, Vera R, Smerdou C, Martisova E, Arozarena I, Wellbrock C, Llopiz D, Ruiz M, Sarobe P, Breckpot K, Kochan G, Escors D. Cell Rep. 2017 Aug 22;20(8):1818-1829. doi: 10.1016/j.celrep.2017.07.075. PMID: 28834746 |
|
50. |
Antigen-presenting cell-targeted lentiviral vectors do not support the development of productive T-cell effector responses: implications for in vivo targeted vaccine delivery.
Goyvaerts C, De Vlaeminck Y, Escors D, Lienenklaus S, Keyaerts M, Raes G, Breckpot K. Gene Ther. 2017 Jun;24(6):370-375. doi: 10.1038/gt.2017.30. Epub 2017 May 25. PMID: 28540936 |
|
51. |
Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers.
Broos K, Keyaerts M, Lecocq Q, Renmans D, Nguyen T, Escors D, Liston A, Raes G, Breckpot K, Devoogdt N. Oncotarget. 2017 Jun 27;8(26):41932-41946. doi: 10.18632/oncotarget.16708. PMID: 28410210 Free PMC article. |
|
52. |
Phosphorylated STAT5 regulates p53 expression via BRCA1/BARD1-NPM1 and MDM2.
Ren Z, Aerts JL, Vandenplas H, Wang JA, Gorbenko O, Chen JP, Giron P, Heirman C, Goyvaerts C, Zacksenhaus E, Minden MD, Stambolic V, Breckpot K, De Grève J. Cell Death Dis. 2016 Dec 22;7(12):e2560. doi: 10.1038/cddis.2016.430. PMID: 28005077 Free PMC article. |
|
53. |
Adjuvant-Enhanced mRNA Vaccines.
Bialkowski L, Van der Jeught K, Renmans D, van Weijnen A, Heirman C, Keyaerts M, Breckpot K, Thielemans K. Methods Mol Biol. 2017;1499:179-191. doi: 10.1007/978-1-4939-6481-9_11. PMID: 27987150 |
|
54. |
Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation.
De Beule N, De Veirman K, Maes K, De Bruyne E, Menu E, Breckpot K, De Raeve H, Van Rampelbergh R, Van Ginderachter JA, Schots R, Van Valckenborgh E, Vanderkerken K. J Pathol. 2017 Mar;241(4):534-546. doi: 10.1002/path.4860. Epub 2017 Jan 30. PMID: 27976373 |
|
55. |
Adult-Derived Human Liver Stem/Progenitor Cells Infused 3 Days Postsurgery Improve Liver Regeneration in a Mouse Model of Extended Hepatectomy.
Herrero A, Prigent J, Lombard C, Rosseels V, Daujat-Chavanieu M, Breckpot K, Najimi M, Deblandre G, Sokal EM. Cell Transplant. 2017 Feb 16;26(2):351-364. doi: 10.3727/096368916X692960. Epub 2016 Sep 21. PMID: 27657746 Free PMC article. |
|
56. |
Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon.
Broos K, Van der Jeught K, Puttemans J, Goyvaerts C, Heirman C, Dewitte H, Verbeke R, Lentacker I, Thielemans K, Breckpot K. Mol Ther Nucleic Acids. 2016 Jun 21;5(6):e326. doi: 10.1038/mtna.2016.38. PMID: 27327138 Free PMC article. |
|
57. |
Cancer-Associated Myeloid Regulatory Cells.
De Vlaeminck Y, González-Rascón A, Goyvaerts C, Breckpot K. Front Immunol. 2016 Mar 29;7:113. doi: 10.3389/fimmu.2016.00113. eCollection 2016. PMID: 27065074 Free PMC article. Review. |
|
58. |
Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy.
Dufait I, Van Valckenborgh E, Menu E, Escors D, De Ridder M, Breckpot K. Oncotarget. 2016 Jul 5;7(27):42698-42715. doi: 10.18632/oncotarget.8311. PMID: 27029037 Free PMC article. Review. |
|
59. |
Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours.
Bialkowski L, van Weijnen A, Van der Jeught K, Renmans D, Daszkiewicz L, Heirman C, Stangé G, Breckpot K, Aerts JL, Thielemans K. Sci Rep. 2016 Mar 2;6:22509. doi: 10.1038/srep22509. PMID: 26931556 Free PMC article. |
|
60. |
Myeloid-derived suppressor cells reveal radioprotective properties through arginase-induced l-arginine depletion.
Leonard W, Dufait I, Schwarze JK, Law K, Engels B, Jiang H, Van den Berge D, Gevaert T, Storme G, Verovski V, Breckpot K, De Ridder M. Radiother Oncol. 2016 May;119(2):291-9. doi: 10.1016/j.radonc.2016.01.014. Epub 2016 Feb 10. PMID: 26874542 |
|
61. |
Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic Cells.
Van Lint S, Renmans D, Broos K, Goethals L, Maenhout S, Benteyn D, Goyvaerts C, Du Four S, Van der Jeught K, Bialkowski L, Flamand V, Heirman C, Thielemans K, Breckpot K. Cancer Immunol Res. 2016 Feb;4(2):146-56. doi: 10.1158/2326-6066.CIR-15-0163. Epub 2015 Dec 11. PMID: 26659303 |
|
62. |
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death.
Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, Breckpot K, Brough D, Chaurio R, Cirone M, Coosemans A, Coulie PG, De Ruysscher D, Dini L, de Witte P, Dudek-Peric AM, Faggioni A, Fucikova J, Gaipl US, Golab J, Gougeon ML, Hamblin MR, Hemminki A, Herrmann M, Hodge JW, Kepp O, Kroemer G, Krysko DV, Land WG, Madeo F, Manfredi AA, Mattarollo SR, Maueroder C, Merendino N, Multhoff G, Pabst T, Ricci JE, Riganti C, Romano E, Rufo N, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Vacchelli E, Vandenabeele P, Vandenberk L, Van den Eynde BJ, Van Gool S, Velotti F, Zitvogel L, Agostinis P. Front Immunol. 2015 Nov 20;6:588. doi: 10.3389/fimmu.2015.00588. eCollection 2015. PMID: 26635802 Free PMC article. |
|
63. |
Hitchhiking nanoparticles: Reversible coupling of lipid-based nanoparticles to cytotoxic T lymphocytes.
Wayteck L, Dewitte H, De Backer L, Breckpot K, Demeester J, De Smedt SC, Raemdonck K. Biomaterials. 2016 Jan;77:243-54. doi: 10.1016/j.biomaterials.2015.11.016. Epub 2015 Nov 10. PMID: 26606450 |
|
64. |
Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines.
Goyvaerts C, Breckpot K. J Immunol Res. 2015;2015:785634. doi: 10.1155/2015/785634. Epub 2015 Oct 25. PMID: 26583156 Free PMC article. Review. |
|
65. |
The transduction pattern of IL-12-encoding lentiviral vectors shapes the immunological outcome.
Goyvaerts C, Broos K, Escors D, Heirman C, Raes G, De Baetselier P, Thielemans K, Breckpot K. Eur J Immunol. 2015 Dec;45(12):3351-61. doi: 10.1002/eji.201545559. Epub 2015 Oct 27. PMID: 26377033 |
|
66. |
Contribution of Cardiac Sodium Channel β-Subunit Variants to Brugada Syndrome.
Peeters U, Scornik F, Riuró H, Pérez G, Komurcu-Bayrak E, Van Malderen S, Pappaert G, Tarradas A, Pagans S, Daneels D, Breckpot K, Brugada P, Bonduelle M, Brugada R, Van Dooren S. Circ J. 2015;79(10):2118-29. doi: 10.1253/circj.CJ-15-0164. Epub 2015 Jul 15. PMID: 26179811 Clinical Trial. |
|
67. |
Intratumoral delivery of mRNA: Overcoming obstacles for effective immunotherapy.
Van der Jeught K, Van Lint S, Thielemans K, Breckpot K. Oncoimmunology. 2015 Feb 3;4(5):e1005504. doi: 10.1080/2162402X.2015.1005504. eCollection 2015 May. PMID: 26155403 Free PMC article. |
|
68. |
Corrigendum: "Combinatorial Strategies for the Induction of Immunogenic Cell Death".
Bezu L, Gomes-da-Silva LC, Dewitte H, Breckpot K, Fucikova J, Spisek R, Galluzzi L, Kepp O, Kroemer G. Front Immunol. 2015 Jun 1;6:275. doi: 10.3389/fimmu.2015.00275. eCollection 2015. PMID: 26082782 Free PMC article. |
|
69. |
Combinatorial strategies for the induction of immunogenic cell death.
Bezu L, Gomes-de-Silva LC, Dewitte H, Breckpot K, Fucikova J, Spisek R, Galluzzi L, Kepp O, Kroemer G. Front Immunol. 2015 Apr 24;6:187. doi: 10.3389/fimmu.2015.00187. eCollection 2015. PMID: 25964783 Free PMC article. Review. |
|
70. |
Consensus guidelines for the detection of immunogenic cell death.
Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fučíková J, Gabriele L, Gaipl US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G, Galluzzi L. Oncoimmunology. 2014 Dec 13;3(9):e955691. doi: 10.4161/21624011.2014.955691. eCollection 2014 Oct. PMID: 25941621 Free PMC article. Review. |
|
71. |
Ex vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer.
Dufait I, Schwarze JK, Liechtenstein T, Leonard W, Jiang H, Escors D, De Ridder M, Breckpot K. Oncotarget. 2015 May 20;6(14):12369-82. doi: 10.18632/oncotarget.3682. PMID: 25869209 Free PMC article. |
|
72. |
Targeting the tumor microenvironment to enhance antitumor immune responses.
Van der Jeught K, Bialkowski L, Daszkiewicz L, Broos K, Goyvaerts C, Renmans D, Van Lint S, Heirman C, Thielemans K, Breckpot K. Oncotarget. 2015 Jan 30;6(3):1359-81. doi: 10.18632/oncotarget.3204. PMID: 25682197 Free PMC article. Review. |
|
73. |
Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity.
Van der Jeught K, Joe PT, Bialkowski L, Heirman C, Daszkiewicz L, Liechtenstein T, Escors D, Thielemans K, Breckpot K. Oncotarget. 2014 Oct 30;5(20):10100-13. doi: 10.18632/oncotarget.2463. PMID: 25338019 Free PMC article. |
|
74. |
The ReNAissanCe of mRNA-based cancer therapy.
Van Lint S, Renmans D, Broos K, Dewitte H, Lentacker I, Heirman C, Breckpot K, Thielemans K. Expert Rev Vaccines. 2015 Feb;14(2):235-51. doi: 10.1586/14760584.2015.957685. Epub 2014 Sep 29. PMID: 25263094 Review. |
|
75. |
mRNA-based dendritic cell vaccines.
Benteyn D, Heirman C, Bonehill A, Thielemans K, Breckpot K. Expert Rev Vaccines. 2015 Feb;14(2):161-76. doi: 10.1586/14760584.2014.957684. Epub 2014 Sep 8. PMID: 25196947 Review. |
|
76. |
The potential of antigen and TriMix sonoporation using mRNA-loaded microbubbles for ultrasound-triggered cancer immunotherapy.
Dewitte H, Van Lint S, Heirman C, Thielemans K, De Smedt SC, Breckpot K, Lentacker I. J Control Release. 2014 Nov 28;194:28-36. doi: 10.1016/j.jconrel.2014.08.011. Epub 2014 Aug 22. PMID: 25151979 |
|
77. |
A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice.
Liechtenstein T, Perez-Janices N, Gato M, Caliendo F, Kochan G, Blanco-Luquin I, Van der Jeught K, Arce F, Guerrero-Setas D, Fernandez-Irigoyen J, Santamaria E, Breckpot K, Escors D. Oncotarget. 2014 Sep 15;5(17):7843-57. doi: 10.18632/oncotarget.2279. PMID: 25151659 Free PMC article. |
|
78. |
Choose your models wisely: how different murine bone marrow-derived dendritic cell protocols influence the success of nanoparticulate vaccines in vitro.
Dewitte H, Verbeke R, Breckpot K, Vandenbroucke RE, Libert C, De Smedt SC, Lentacker I. J Control Release. 2014 Dec 10;195:138-46. doi: 10.1016/j.jconrel.2014.06.024. Epub 2014 Jun 21. PMID: 24960224 |
|
79. |
Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula.
Van Lint S, Wilgenhof S, Heirman C, Corthals J, Breckpot K, Bonehill A, Neyns B, Thielemans K. Cancer Immunol Immunother. 2014 Sep;63(9):959-67. doi: 10.1007/s00262-014-1558-3. Epub 2014 May 31. PMID: 24878889 Review. |
|
80. |
Phosphorylated STAT3 physically interacts with NPM and transcriptionally enhances its expression in cancer.
Ren Z, Aerts JL, Pen JJ, Heirman C, Breckpot K, De Grève J. Oncogene. 2015 Mar 26;34(13):1650-7. doi: 10.1038/onc.2014.109. Epub 2014 May 5. PMID: 24793791 |
|
81. |
Immunogenicity of targeted lentivectors.
Goyvaerts C, Kurt de G, Van Lint S, Heirman C, Van Ginderachter JA, De Baetselier P, Raes G, Thielemans K, Breckpot K. Oncotarget. 2014 Feb 15;5(3):704-15. doi: 10.18632/oncotarget.1680. PMID: 24519916 Free PMC article. |
|
82. |
Role of non-classical MHC class I molecules in cancer immunosuppression.
Kochan G, Escors D, Breckpot K, Guerrero-Setas D. Oncoimmunology. 2013 Nov 1;2(11):e26491. doi: 10.4161/onci.26491. Epub 2013 Oct 21. PMID: 24482746 Free PMC article. Review. |
|
83. |
Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells.
Pen JJ, Keersmaecker BD, Heirman C, Corthals J, Liechtenstein T, Escors D, Thielemans K, Breckpot K. Gene Ther. 2014 Mar;21(3):262-71. doi: 10.1038/gt.2013.80. Epub 2014 Jan 9. PMID: 24401835 |
|
84. |
Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy.
Liechtenstein T, Perez-Janices N, Blanco-Luquin I, Goyvaerts C, Schwarze J, Dufait I, Lanna A, Ridder M, Guerrero-Setas D, Breckpot K, Escors D. Oncoimmunology. 2014 Jul 3;3(7):e945378. doi: 10.4161/21624011.2014.945378. eCollection 2014. PMID: 25954597 Free PMC article. |
|
85. |
Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo.
Benteyn D, Anguille S, Van Lint S, Heirman C, Van Nuffel AM, Corthals J, Ochsenreither S, Waelput W, Van Beneden K, Breckpot K, Van Tendeloo V, Thielemans K, Bonehill A. Mol Ther Nucleic Acids. 2013 Nov 19;2(11):e134. doi: 10.1038/mtna.2013.54. PMID: 24253259 Free PMC article. |
|
86. |
Assessing T-cell responses in anticancer immunotherapy: Dendritic cells or myeloid-derived suppressor cells?
Escors D, Liechtenstein T, Perez-Janices N, Schwarze J, Dufait I, Goyvaerts C, Lanna A, Arce F, Blanco-Luquin I, Kochan G, Guerrero-Setas D, Breckpot K. Oncoimmunology. 2013 Oct 1;2(10):e26148. doi: 10.4161/onci.26148. Epub 2013 Sep 12. PMID: 24244902 Free PMC article. Review. |
|
87. |
Gain of 20q11.21 in human embryonic stem cells improves cell survival by increased expression of Bcl-xL.
Nguyen HT, Geens M, Mertzanidou A, Jacobs K, Heirman C, Breckpot K, Spits C. Mol Hum Reprod. 2014 Feb;20(2):168-77. doi: 10.1093/molehr/gat077. Epub 2013 Nov 11. PMID: 24217388 |
|
88. |
A personalized view on cancer immunotherapy.
Wayteck L, Breckpot K, Demeester J, De Smedt SC, Raemdonck K. Cancer Lett. 2014 Sep 28;352(1):113-25. doi: 10.1016/j.canlet.2013.09.016. Epub 2013 Sep 17. PMID: 24051308 Review. |
|
89. |
Targeting of human antigen-presenting cell subsets.
Goyvaerts C, Dingemans J, De Groeve K, Heirman C, Van Gulck E, Vanham G, De Baetselier P, Thielemans K, Raes G, Breckpot K. J Virol. 2013 Oct;87(20):11304-8. doi: 10.1128/JVI.01498-13. Epub 2013 Jul 17. PMID: 23864630 Free PMC article. |
|
90. |
Modulation of regulatory T cell function by monocyte-derived dendritic cells matured through electroporation with mRNA encoding CD40 ligand, constitutively active TLR4, and CD70.
Pen JJ, De Keersmaecker B, Maenhout SK, Van Nuffel AM, Heirman C, Corthals J, Escors D, Bonehill A, Thielemans K, Breckpot K, Aerts JL. J Immunol. 2013 Aug 15;191(4):1976-83. doi: 10.4049/jimmunol.1201008. Epub 2013 Jul 10. PMID: 23842750 |
|
91. |
Downregulation of Stat3 in melanoma: reprogramming the immune microenvironment as an anticancer therapeutic strategy.
Emeagi PU, Maenhout S, Dang N, Heirman C, Thielemans K, Breckpot K. Gene Ther. 2013 Nov;20(11):1085-92. doi: 10.1038/gt.2013.35. Epub 2013 Jun 27. PMID: 23804077 |
|
92. |
Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model.
Nur H, Fostier K, Aspeslagh S, Renmans W, Bertrand E, Leleu X, Favreau M, Breckpot K, Schots R, De Waele M, Van Valckenborgh E, De Bruyne E, Facon T, Elewaut D, Vanderkerken K, Menu E. PLoS One. 2013 May 31;8(5):e65075. doi: 10.1371/journal.pone.0065075. Print 2013. PMID: 23741460 Free PMC article. |
|
93. |
Immune modulation by genetic modification of dendritic cells with lentiviral vectors.
Liechtenstein T, Perez-Janices N, Bricogne C, Lanna A, Dufait I, Goyvaerts C, Laranga R, Padella A, Arce F, Baratchian M, Ramirez N, Lopez N, Kochan G, Blanco-Luquin I, Guerrero-Setas D, Breckpot K, Escors D. Virus Res. 2013 Sep;176(1-2):1-15. doi: 10.1016/j.virusres.2013.05.007. Epub 2013 May 28. PMID: 23726846 Review. |
|
94. |
Retroviral and lentiviral vectors for the induction of immunological tolerance.
Dufait I, Liechtenstein T, Lanna A, Bricogne C, Laranga R, Padella A, Breckpot K, Escors D. Scientifica (Cairo). 2012 Dec;2012:694137. doi: 10.6064/2012/694137. PMID: 23526794 Free PMC article. |
|
95. |
PD-L1/PD-1 Co-Stimulation, a Brake for T cell Activation and a T cell Differentiation Signal.
Liechtenstein T, Dufait I, Bricogne C, Lanna A, Pen J, Breckpot K, Escors D. J Clin Cell Immunol. 2012 Oct 30;S12:006. doi: 10.4172/2155-9899.S12-006. PMID: 23525238 Free PMC article. |
|
96. |
mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic.
Van Lint S, Heirman C, Thielemans K, Breckpot K. Hum Vaccin Immunother. 2013 Feb;9(2):265-74. doi: 10.4161/hv.22661. Epub 2013 Jan 4. PMID: 23291946 Free PMC article. Review. |
|
97. |
The role of SMAC mimetics in regulation of tumor cell death and immunity.
Emeagi PU, Thielemans K, Breckpot K. Oncoimmunology. 2012 Sep 1;1(6):965-967. doi: 10.4161/onci.20369. PMID: 23162773 Free PMC article. |
|
98. |
Targeting lentiviral vectors for cancer immunotherapy.
Arce F, Breckpot K, Collins M, Escors D. Curr Cancer Ther Rev. 2011 Nov;7(4):248-260. doi: 10.2174/157339411797642605. PMID: 22983382 Free PMC article. |
|
99. |
Lentiviral vectors: a versatile tool to fight cancer.
Emeagi PU, Goyvaerts C, Maenhout S, Pen J, Thielemans K, Breckpot K. Curr Mol Med. 2013 May;13(4):602-25. doi: 10.2174/1566524011313040011. PMID: 22973872 Review. |
|
100. |
MODULATING CO-STIMULATION DURING ANTIGEN PRESENTATION TO ENHANCE CANCER IMMUNOTHERAPY.
Liechtenstein T, Dufait I, Lanna A, Breckpot K, Escors D. Immunol Endocr Metab Agents Med Chem. 2012 Sep;12(3):224-235. doi: 10.2174/187152212802001875. PMID: 22945252 Free PMC article. |
|
101. |
Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages.
Movahedi K, Schoonooghe S, Laoui D, Houbracken I, Waelput W, Breckpot K, Bouwens L, Lahoutte T, De Baetselier P, Raes G, Devoogdt N, Van Ginderachter JA. Cancer Res. 2012 Aug 15;72(16):4165-77. doi: 10.1158/0008-5472.CAN-11-2994. Epub 2012 Jun 19. PMID: 22719068 |
|
102. |
Proinflammatory characteristics of SMAC/DIABLO-induced cell death in antitumor therapy.
Emeagi PU, Van Lint S, Goyvaerts C, Maenhout S, Cauwels A, McNeish IA, Bos T, Heirman C, Thielemans K, Aerts JL, Breckpot K. Cancer Res. 2012 Mar 15;72(6):1342-52. doi: 10.1158/0008-5472.CAN-11-2400. Epub 2012 Feb 29. PMID: 22379024 |
|
103. |
Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy.
Van Lint S, Goyvaerts C, Maenhout S, Goethals L, Disy A, Benteyn D, Pen J, Bonehill A, Heirman C, Breckpot K, Thielemans K. Cancer Res. 2012 Apr 1;72(7):1661-71. doi: 10.1158/0008-5472.CAN-11-2957. Epub 2012 Feb 15. PMID: 22337996 |
|
104. |
Inhibition of firefly luciferase by general anesthetics: effect on in vitro and in vivo bioluminescence imaging.
Keyaerts M, Remory I, Caveliers V, Breckpot K, Bos TJ, Poelaert J, Bossuyt A, Lahoutte T. PLoS One. 2012;7(1):e30061. doi: 10.1371/journal.pone.0030061. Epub 2012 Jan 10. PMID: 22253879 Free PMC article. |
|
105. |
Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells.
Goyvaerts C, De Groeve K, Dingemans J, Van Lint S, Robays L, Heirman C, Reiser J, Zhang XY, Thielemans K, De Baetselier P, Raes G, Breckpot K. Gene Ther. 2012 Dec;19(12):1133-40. doi: 10.1038/gt.2011.206. Epub 2012 Jan 12. PMID: 22241177 Free PMC article. |
|
106. |
Selective activation of intracellular signalling pathways in dendritic cells for cancer immunotherapy.
Arce F, Kochan G, Breckpot K, Stephenson H, Escors D. Anticancer Agents Med Chem. 2012 Jan;12(1):29-39. doi: 10.2174/187152012798764679. PMID: 21707504 Review. |
|
107. |
mRNA: delivering an antitumor message?
Van Lint S, Thielemans K, Breckpot K. Immunotherapy. 2011 May;3(5):605-7. doi: 10.2217/imt.11.28. PMID: 21554090 |
|
108. |
Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis.
Arce F, Breckpot K, Stephenson H, Karwacz K, Ehrenstein MR, Collins M, Escors D. Arthritis Rheum. 2011 Jan;63(1):84-95. doi: 10.1002/art.30099. PMID: 20967853 Free PMC article. |
|
109. |
Primary deficiency of microsomal triglyceride transfer protein in human abetalipoproteinemia is associated with loss of CD1 function.
Zeissig S, Dougan SK, Barral DC, Junker Y, Chen Z, Kaser A, Ho M, Mandel H, McIntyre A, Kennedy SM, Painter GF, Veerapen N, Besra GS, Cerundolo V, Yue S, Beladi S, Behar SM, Chen X, Gumperz JE, Breckpot K, Raper A, Baer A, Exley MA, Hegele RA, Cuchel M, Rader DJ, Davidson NO, Blumberg RS. J Clin Invest. 2010 Aug;120(8):2889-99. doi: 10.1172/JCI42703. Epub 2010 Jul 1. PMID: 20592474 Free PMC article. |
|
110. |
HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7.
Breckpot K, Escors D, Arce F, Lopes L, Karwacz K, Van Lint S, Keyaerts M, Collins M. J Virol. 2010 Jun;84(11):5627-36. doi: 10.1128/JVI.00014-10. Epub 2010 Mar 17. PMID: 20237085 Free PMC article. |
|
111. |
Lentiviral vectors in gene therapy: their current status and future potential.
Escors D, Breckpot K. Arch Immunol Ther Exp (Warsz). 2010 Apr;58(2):107-19. doi: 10.1007/s00005-010-0063-4. Epub 2010 Feb 9. PMID: 20143172 Free PMC article. Review. |
|
112. |
Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification.
Breckpot K, Escors D. Endocr Metab Immune Disord Drug Targets. 2009 Dec;9(4):328-43. doi: 10.2174/187153009789839156. PMID: 19857199 Free PMC article. Review. |
|
113. |
Variegation and silencing in a lentiviral-based murine transgenic model.
Baup D, Fraga L, Pernot E, Van Acker A, Vanherck AS, Breckpot K, Thielemans K, Schurmans S, Moser M, Leo O. Transgenic Res. 2010 Jun;19(3):399-414. doi: 10.1007/s11248-009-9318-4. Epub 2009 Aug 23. PMID: 19701794 |
|
114. |
Attenuated expression of A20 markedly increases the efficacy of double-stranded RNA-activated dendritic cells as an anti-cancer vaccine.
Breckpot K, Aerts-Toegaert C, Heirman C, Peeters U, Beyaert R, Aerts JL, Thielemans K. J Immunol. 2009 Jan 15;182(2):860-70. doi: 10.4049/jimmunol.182.2.860. PMID: 19124729 |
|
115. |
Lentiviral vectors for anti-tumor immunotherapy.
Breckpot K, Emeagi PU, Thielemans K. Curr Gene Ther. 2008 Dec;8(6):438-48. doi: 10.2174/156652308786848058. PMID: 19075627 Review. |
|
116. |
Functional T-cell responses generated by dendritic cells expressing the early HIV-1 proteins Tat, Rev and Nef.
Allard SD, Pletinckx K, Breckpot K, Heirman C, Bonehill A, Michiels A, van Baalen CA, Gruters RA, Osterhaus AD, Lacor P, Thielemans K, Aerts JL. Vaccine. 2008 Jul 4;26(29-30):3735-41. doi: 10.1016/j.vaccine.2008.04.077. Epub 2008 May 20. PMID: 18539368 |
|
117. |
Tissue-targeted therapy of autoimmune diabetes using dendritic cells transduced to express IL-4 in NOD mice.
Creusot RJ, Yaghoubi SS, Kodama K, Dang DN, Dang VH, Breckpot K, Thielemans K, Gambhir SS, Fathman CG. Clin Immunol. 2008 May;127(2):176-87. doi: 10.1016/j.clim.2007.12.009. Epub 2008 Mar 12. PMID: 18337172 Free PMC article. |
|
118. |
Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of D: -luciferin: effect on intensity, time kinetics and repeatability of photon emission.
Keyaerts M, Verschueren J, Bos TJ, Tchouate-Gainkam LO, Peleman C, Breckpot K, Vanhove C, Caveliers V, Bossuyt A, Lahoutte T. Eur J Nucl Med Mol Imaging. 2008 May;35(5):999-1007. doi: 10.1007/s00259-007-0664-2. Epub 2008 Jan 4. PMID: 18180921 |
|
119. |
Activation of immature monocyte-derived dendritic cells after transduction with high doses of lentiviral vectors.
Breckpot K, Emeagi P, Dullaers M, Michiels A, Heirman C, Thielemans K. Hum Gene Ther. 2007 Jun;18(6):536-46. doi: 10.1089/hum.2007.006. PMID: 17576158 |
|
120. |
Current approaches in dendritic cell generation and future implications for cancer immunotherapy.
Tuyaerts S, Aerts JL, Corthals J, Neyns B, Heirman C, Breckpot K, Thielemans K, Bonehill A. Cancer Immunol Immunother. 2007 Oct;56(10):1513-37. doi: 10.1007/s00262-007-0334-z. Epub 2007 May 15. PMID: 17503040 Review. |
|
121. |
Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells.
Tuyaerts S, Van Meirvenne S, Bonehill A, Heirman C, Corthals J, Waldmann H, Breckpot K, Thielemans K, Aerts JL. J Leukoc Biol. 2007 Jul;82(1):93-105. doi: 10.1189/jlb.0906568. Epub 2007 Apr 20. PMID: 17449724 |
|
122. |
Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics.
Breckpot K, Aerts JL, Thielemans K. Gene Ther. 2007 Jun;14(11):847-62. doi: 10.1038/sj.gt.3302947. Epub 2007 Mar 22. PMID: 17361214 Review. |
|
123. |
CD83 expression on dendritic cells and T cells: correlation with effective immune responses.
Aerts-Toegaert C, Heirman C, Tuyaerts S, Corthals J, Aerts JL, Bonehill A, Thielemans K, Breckpot K. Eur J Immunol. 2007 Mar;37(3):686-95. doi: 10.1002/eji.200636535. PMID: 17301951 |
|
124. |
Induction of antigen-specific CD8+ cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA.
Michiels A, Breckpot K, Corthals J, Tuyaerts S, Bonehill A, Heirman C, Thielemans K, Aerts JL. Gene Ther. 2006 Jul;13(13):1027-36. doi: 10.1038/sj.gt.3302750. Epub 2006 Mar 2. PMID: 16511519 |
|
125. |
Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors.
Dullaers M, Van Meirvenne S, Heirman C, Straetman L, Bonehill A, Aerts JL, Thielemans K, Breckpot K. Gene Ther. 2006 Apr;13(7):630-40. doi: 10.1038/sj.gt.3302697. PMID: 16355115 |
|
126. |
Dendritic cells differentiated in the presence of IFN-{beta} and IL-3 are potent inducers of an antigen-specific CD8+ T cell response.
Breckpot K, Corthals J, Bonehill A, Michiels A, Tuyaerts S, Aerts C, Heirman C, Thielemans K. J Leukoc Biol. 2005 Oct;78(4):898-908. doi: 10.1189/jlb.0105052. Epub 2005 Jul 21. PMID: 16037410 |
|
127. |
Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines.
Michiels A, Tuyaerts S, Bonehill A, Corthals J, Breckpot K, Heirman C, Van Meirvenne S, Dullaers M, Allard S, Brasseur F, van der Bruggen P, Thielemans K. Gene Ther. 2005 May;12(9):772-82. doi: 10.1038/sj.gt.3302471. PMID: 15750615 |
|
128. |
Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells.
Breckpot K, Heirman C, Neyns B, Thielemans K. J Gene Med. 2004 Nov;6(11):1175-88. doi: 10.1002/jgm.615. PMID: 15468193 Review. |
|
129. |
Side-by-side comparison of lentivirally transduced and mRNA-electroporated dendritic cells: implications for cancer immunotherapy protocols.
Dullaers M, Breckpot K, Van Meirvenne S, Bonehill A, Tuyaerts S, Michiels A, Straetman L, Heirman C, De Greef C, Van Der Bruggen P, Thielemans K. Mol Ther. 2004 Oct;10(4):768-79. doi: 10.1016/j.ymthe.2004.07.017. PMID: 15451461 |
|
130. |
Activation of monocytes via the CD14 receptor leads to the enhanced lentiviral transduction of immature dendritic cells.
Breckpot K, Corthals J, Heirman C, Bonehill A, Michiels A, Tuyaerts S, De Greef C, Thielemans K. Hum Gene Ther. 2004 Jun;15(6):562-73. doi: 10.1089/104303404323142015. PMID: 15212715 |
|
131. |
Human pancreatic duct cells can produce tumour necrosis factor-alpha that damages neighbouring beta cells and activates dendritic cells.
Movahedi B, Van de Casteele M, Caluwé N, Stangé G, Breckpot K, Thielemans K, Vreugdenhil G, Mathieu C, Pipeleers D. Diabetologia. 2004 Jun;47(6):998-1008. doi: 10.1007/s00125-004-1426-3. Epub 2004 Jun 8. PMID: 15184981 |
|
132. |
Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules.
Bonehill A, Heirman C, Tuyaerts S, Michiels A, Breckpot K, Brasseur F, Zhang Y, Van Der Bruggen P, Thielemans K. J Immunol. 2004 Jun 1;172(11):6649-57. doi: 10.4049/jimmunol.172.11.6649. PMID: 15153480 |
|
133. |
Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses.
Breckpot K, Heirman C, De Greef C, van der Bruggen P, Thielemans K. J Immunol. 2004 Feb 15;172(4):2232-7. doi: 10.4049/jimmunol.172.4.2232. PMID: 14764691 |
|
134. |
Lentivirally transduced dendritic cells as a tool for cancer immunotherapy.
Breckpot K, Dullaers M, Bonehill A, van Meirvenne S, Heirman C, de Greef C, van der Bruggen P, Thielemans K. J Gene Med. 2003 Aug;5(8):654-67. doi: 10.1002/jgm.400. PMID: 12898635 |
|
135. |
Generation of large numbers of dendritic cells in a closed system using Cell Factories.
Tuyaerts S, Noppe SM, Corthals J, Breckpot K, Heirman C, De Greef C, Van Riet I, Thielemans K. J Immunol Methods. 2002 Jun 1;264(1-2):135-51. doi: 10.1016/s0022-1759(02)00099-6. PMID: 12191517 |
Mijn media ervaring
Interviews voor geschreven pers zoals Artsenkrant, Het Laatste Nieuws, Bioinsights, etc.
Podcasts voor Researcher Live (T-cell series) and Sanofi (RNA in Cancer Immunotherapy - planned).